Home Online Features U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Hand-out
Press Releases
Celltrion  
March 9, 2025

U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDARegulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with

logo salamanca press

Salamanca Press

email salamanca press
Local & Social